XML 13 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Balance Sheets - USD ($)
Sep. 30, 2018
Dec. 31, 2017
ASSETS    
Cash and cash equivalents $ 14,374,344 $ 29,163,200
Restricted cash 0 5,004,789
Marketable securities 31,775,525 25,916,681
Prepaid and other current assets 1,102,979 1,312,503
Total current assets 47,252,848 61,397,173
Property and equipment, net 182,603 256,905
Other assets 418,150 1,721,604
Total assets 47,853,601 63,375,682
Liabilities    
Accounts payable 447,219 1,343,089
Accrued liabilities 4,444,844 7,810,948
Notes payable, current 0 159,180
Total current liabilities 4,892,063 9,313,217
Other long-term liabilities 2,152,258 3,872,679
Total liabilities 7,044,321 13,185,896
Commitments and Contingencies
Stockholders' Equity    
Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 1 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at September 30, 2018 and December 31, 2017, respectively 100 100
Common stock, $0.001 par value, authorized 500,000,000 shares; issued and outstanding, 9,853,063 and 9,483,911 shares at September 30, 2018 and December 31, 2017, respectively 9,853 9,484
Additional paid-in capital 436,227,287 433,044,209
Treasury stock, at cost; 11,080 shares at September 30, 2018 and December 31, 2017 (707,637) (707,637)
Accumulated deficit (394,419,255) (381,810,109)
Accumulated other comprehensive loss (28,621) (27,978)
Total Caladrius Biosciences, Inc. stockholders' equity 41,081,727 50,508,069
Noncontrolling interests (272,447) (318,283)
Total stockholders' equity 40,809,280 50,189,786
Liabilities and Equity, Total $ 47,853,601 $ 63,375,682